Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Defining the role of the immune system in cancer treatment: highlights from the Immunochemotherapy Conference.

Demaria S.

Expert Rev Anticancer Ther. 2011 Jun;11(6):841-3. doi: 10.1586/era.11.57. Erratum in: Expert Rev Anticancer Ther. 2011 Aug;11(8):1316.

PMID:
21707279
2.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

3.

The immune system--is it relevant to cancer development, progression and treatment?

Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. Epub 2007 Nov 26. Review.

PMID:
18037277
4.

Immunological aspects of cancer chemotherapy.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.

Nat Rev Immunol. 2008 Jan;8(1):59-73. Review.

PMID:
18097448
5.

Effect of cancer therapy on host response and immunobiology.

Ehrke MJ.

Curr Opin Oncol. 1991 Dec;3(6):1070-7. Review.

PMID:
1843109
6.

Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play.

Debatin KM.

J Natl Cancer Inst. 1997 Jun 4;89(11):750-1. Review. No abstract available.

PMID:
9182966
7.

Vitamin C as a cancer treatment: state of the science and recommendations for research.

Tamayo C, Richardson MA.

Altern Ther Health Med. 2003 May-Jun;9(3):94-101. Review. No abstract available.

PMID:
12776480
8.

How to improve the immunogenicity of chemotherapy and radiotherapy.

Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, Zitvogel L.

Cancer Metastasis Rev. 2011 Mar;30(1):71-82. doi: 10.1007/s10555-011-9283-2. Review.

PMID:
21298323
9.

Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment.

Cavanagh WA, Tjoa BA, Ragde H.

Urology. 2007 Dec;70(6 Suppl):36-41. doi: 10.1016/j.urology.2007.06.1127. Review.

PMID:
18194710
10.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
11.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951
12.

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.

Emens LA, Jaffee EM.

Cancer Res. 2005 Sep 15;65(18):8059-64. Review.

13.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
14.

The effects of nutrition and treatment of cancer on host immunocompetence.

Ota DM, Copeland EM 3rd, Corriere JN Jr, Dudrick SJ.

Surg Gynecol Obstet. 1979 Jan;148(1):104-11.

PMID:
364703
15.

21st International Congress on Anticancer Treatment.

Magné N, Pacaut C, Chargari C.

Expert Rev Anticancer Ther. 2010 May;10(5):647-9. doi: 10.1586/era.10.39.

PMID:
20469995
16.
18.

National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.

National Institutes of Health Consensus Development Panel.

J Natl Cancer Inst Monogr. 2001;(30):5-15. Review.

PMID:
11773285
19.

Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?

Fry TJ, Lankester AC.

Hematol Oncol Clin North Am. 2010 Feb;24(1):109-27. doi: 10.1016/j.hoc.2009.11.010. Review.

PMID:
20113898
20.

[The 2014 Georges Mathé award rewards a research project on the role of the immune system in the success of anti-cancer therapy].

Gaston-Mathé Y.

Bull Cancer. 2014 Nov;101(11):1059-60. French. No abstract available.

PMID:
25580501

Supplemental Content

Support Center